ID
36124
Description
Study ID: 101468/198 Clinical Study ID: 101468/198 Study Title:An open, randomised, crossover, healthy volunteer study to compare the PK and tolerability of ropinirole as 3 different new formulations with the standard marketed formulation and to study the effects of a high fat meal on a new formulation Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Restless Legs Syndrome The Study consists of a Screening, 5 Sessions each with 2 days and a Follow-up. This document contains the Follow-Up Physical Examination form. It has to be filled in for follow-up.
Keywords
Versions (1)
- 4/16/19 4/16/19 -
Copyright Holder
GlaxoSmithKline
Uploaded on
April 16, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Comparison of pharmacokinetic and tolerability of ropinirole in healthy adults, 101468/198
Follow-Up Physical Examination
- StudyEvent: ODM
Description
Physical Examination
Alias
- UMLS CUI-1
- C0031809
Description
day month year
Data type
date
Alias
- UMLS CUI [1]
- C2985720
Description
00.00-23:59
Data type
time
Alias
- UMLS CUI [1]
- C2826761
Description
Change from last examination
Data type
text
Alias
- UMLS CUI [1,1]
- C0031809
- UMLS CUI [1,2]
- C0443172
Description
Change, specification
Data type
text
Alias
- UMLS CUI [1,1]
- C0031809
- UMLS CUI [1,2]
- C0034869
Similar models
Follow-Up Physical Examination
- StudyEvent: ODM
C0443172 (UMLS CUI [1,2])
C0034869 (UMLS CUI [1,2])
No comments